American Cancer Society. Statistics for 2007. American Cancer Society. Available at http://www.cancer.org/docroot/STT/STT_0.asp. Accessed November, 2007.

Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol. Mar 1969;101(3):297-301. [Medline].

Jonasch et al. Renal Cell Carcinoma. In: Kantarjian HM, Wolff RA, Koller CA, eds. MD Anderson Manual of Medical Oncology. New York, NY: McGraw-Hill; 2006.

Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. Dec 1 2002;20(23):4559-66. [Medline].

Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol. Apr 2000;27(2):177-86. [Medline].

Atzpodien J, Kirchner H, Hanninen EL, et al. European studies of interleukin-2 in metastatic renal cell carcinoma. Semin Oncol. Dec 1993;20(6 Suppl 9):22-6. [Medline].

Bukowski RM. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol. Apr 2000;27(2):204-12. [Medline].

Fisher RI, Rosenberg SA, Sznol M, et al. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am. Dec 1997;3 Suppl 1:S70-2. [Medline].

Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. Dec 6 2001;345(23):1655-9. [Medline].

Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma whoreceived high-dose recombinant interleukin-2 therapy. J Clin Oncol. Mar 1995;13(3):688-96. [Medline].

Holtl L, Rieser C, Papesh C, et al. CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet. Oct 24 1998;352(9137):1358. [Medline].

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. May 31 2007;356(22):2271-81. [Medline].

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. May 31 2007;356(22):2271-81. [Medline].

Javidan J, Stricker HJ, Tamboli P, et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol. Oct 1999;162(4):1277-81. [Medline].

Linehan MW, Berton Z, Bates S. Cancer of Kidney and Ureter. In: Devita VT Jr, et al eds. Principles and Practice of Oncology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:1362-1396.

Minasian LM, Motzer RJ, Gluck L, et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol. Jul 1993;11(7):1368-75. [Medline].

Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. Sep 19 1996;335(12):865-75. [Medline].

Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. Aug 1999;17(8):2530-40. [Medline].

Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. Jan 1 2006;24(1):16-24. [Medline].

Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. Feb 2000;163(2):408-17. [Medline]

.

 

 

 

 

 

 

 

S

 

 

 

 

UTENT  [Package Insert]. New York, NY: Pfizer, Inc. 2006.Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of- life scores. J Clin Oncol. Jan 1998;16(1):139-44. [Medline].

Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. Sep 1999;17(9):2859-67. [Medline].

Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol. Jan 1994;12(1):206-12. [Medline].

Rini BI, Vogelzang NJ, Dumas MC, et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. Jun 2000;18(12):2419-26. [Medline].

Sleijfer DT, Janssen RA, Buter J, et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advancedrenal cell cancer on an outpatient basis. J Clin Oncol. Jul 1992;10(7):1119-23. [Medline].

Stadler WM, Vogelzang NJ. Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Semin Oncol. Feb 1995;22(1):67-73. [Medline].

Van Brussel JP, Mickisch GH. Prognostic factors in renal cell and bladder cancer. BJU Int. May 1999;83(8):902-8; quiz 908-9. [Medline].

Vogelzang NJ, Stadler WM. Kidney cancer. Lancet. Nov 21 1998;352(9141):1691-6. [Medline].

Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol. Feb 1995;22(1):42-60. [Medline].

Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factorantibody, for metastatic renal cancer. N Engl J Med. Jul 31 2003;349(5):427-34. [Medline].